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Background: Cystic fibrosis (CF) is a fatal genetic disorder caused by mutations in the CF transmembrane
conductance regulator (CFTR) gene that primarily affects the lungs and the digestive system, and the current drug
treatment is mainly able to alleviate symptoms. To improve disease management for CF, we considered the
repurposing of approved drugs and hypothesized that specific microRNA (miRNA) transcription factors (TF) gene
networks can be used to generate feed-forward loops (FFLs), thus providing treatment opportunities on the basis
of disease specific FFLs.
Methods: Comprehensive database searches revealed significantly enriched TFs and miRNAs in CF and CFTR gene
networks. The target genes were validated using ChIPBase and by employing a consensus approach of diverse
algorithms to predict miRNA gene targets. STRING analysis confirmed protein-protein interactions (PPIs) among
network partners and motif searches defined composite FFLs. Using information extracted from SM2miR and
Pharmaco-miR, an in silico drug repurposing pipeline was established based on the regulation of miRNA/TFs in
CF/CFTR networks.
Results: In human airway epithelium, a total of 15 composite FFLs were constructed based on CFTR specific
miRNA/TF gene networks. Importantly, nine of them were confirmed in patient samples and CF epithelial cells lines,
and STRING PPI analysis provided evidence that the targets interacted with each other. Functional analysis revealed
that ubiquitin-mediated proteolysis and protein processing in the endoplasmic reticulum dominate the composite
FFLs, whose major functions are folding, sorting, and degradation. Given that the mutated CFTR gene disrupts the
function of the chloride channel, the constructed FFLs address mechanistic aspects of the disease and, among 48
repurposing drug candidates, 26 were confirmed with literature reports and/or existing clinical trials relevant to the
treatment of CF patients.
Conclusion: The construction of FFLs identified promising drug repurposing candidates for CF and the developed
strategy may be applied to other diseases as well.Background
Cystic fibrosis (CF) is a lethal autosomal recessive disorder
that mostly affects Caucasians with approximately 30,000
cases in the United States and about 70,000 cases reported
worldwide. It is caused by mutations in the CF transmem-
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transport of chloride and the movement of water through
an epithelial barrier. Mutations in the CFTR results in
altered mucus and thickened secretions to promote
chronic infection and inflammation [1]. Note that the mu-
tations are grouped into different classes either affecting
the quantity or function or a combination of both of the
CFTR protein. Although the molecular causes for CF are
well understood and >1,000 mutations have been identified,
the treatment of CF is complex and mostly relies on the use
of antibiotics. Currently, there is no cure for CF and drug
treatment can only ease symptoms by influencing mucusThis is an Open Access article distributed under the terms of the Creative
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the prevention of inflammation and infection, and by the
combined use of nutritional supplements [2]. Despite
some advances in the treatment and management of dis-
ease, the median age of survival for CF patients is still only
about 40 years [2].
In 2012, the US Food and Drug Administration (FDA)
approved Kalydeco (ivacaftor) for its use in CF patients.
This drug modulates CFTR activity and fulfilled a promise
made more than 20 years ago when a mutated CFTR was
first discovered and researchers spoke optimistically about
developing drugs to restore the function of the mutated
protein [3]. The successful development of Kalydeco is a
milestone in the treatment of CF patients; however
whether patients will be able to afford the drug is unclear,
making its widespread adoption and use questionable. In
the UK, regulators only agreed to approve Kalydeco after
Vertex Pharmaceuticals reduced its official list price to
£182,625 ($297,000) per year per patient [4] and the drug
is intended for use in CF patients of the G551D genotype
only and must be aged 6 years and above.
Importantly, to address unmet needs in rare and neglected
diseases, drug repurposing of approved drugs has been ad-
vocated and attracted significant attention from academia,
pharmaceutical industry and governmental agencies [5,6]
and included the use of statins (e.g., simvastatin) for the
treatment of adult CF [7]. Apart from its lipid-lowering ef-
fects, statins influence the production of pro-inflammatory
cytokines and chemokines. Moreover, statins modulate nitric
oxide (NO) production by inhibiting the RhoGTPase path-
way, thereby improving NO and inflammatory components
in pathogen infected lungs of CF patients [8], as evidenced
in clinical studies [9,10].
An identification of drug-repurposing candidates for
CF based on a systematic analysis of an entire drug land-
scape has not been attempted. We therefore explored a
computational strategy based on the drug-repurposing
principle that integrates diverse data, including data
from emerging molecular technologies such as expres-
sion of microRNA (miRNA), and transcription factors
(TFs) to promote the rational use of market drugs for
the treatment of CF.
For this purpose, feed-forward loops (FFL) were con-
structed and FFLs are defined as regulatory network motifs,
whose connectivity patterns occur much more frequently
than randomized in ‘control’ networks [11]. A FFL usually
consists of two regulatory elements, one of which controls
the other to regulate gene expression together [11]. FFLs
have been demonstrated to play important roles in disease
development and contributed to an understanding of
underlying mechanism [12]. For instance, the two regula-
tory elements can be defined as two TFs or one TF plus
one miRNA. Taylor et al. [13] detected a nuclear factor,
erythroid 2-related factor (Nrf2), that regulated a FFL whichwas involved in the protective response to oxidative stress
in a mouse disease model. Hall et al. [12] reported a type I
interferon (IFN) FFL in the pathogenesis of autoimmune
rheumatic diseases. Guo et al. [14] identified 32 schizophre-
nia specific FFLs consisting of miRNA, TF, and genes.
Afshar et al. [15] explored FFLs entailing miRNAs, TFs,
and genes in prostate cancer. These proof of concept stud-
ies encourage the development of disease specific FFL that
can be applied to the process of drug repurposing. Here we
hypothesized the existence of a set of FFLs in CF where the
two regulatory elements are defined by specific TFs and
miRNAs, respectively.
Notably, miRNAs are 18 to 25 nt long non-coding RNAs
that function in the transcriptional and post-transcriptional
regulation of gene expression [16]. miRNAs are involved in
different biological processes such as differentiation, apop-
tosis, and stress response [17], and miRNAs can interact
with the 3′UTR of target mRNAs via base-pairing to facili-
tate the recruitment of a ribonucleoprotein complex that ei-
ther blocks cap-dependent translation or triggers target
mRNA deadenylation and degradation [17]. An increasing
number of miRNAs have been identified to regulate cancers
[18,19], multiple sclerosis [20], diabetes [21], hepatotoxicity
[22], and cardiovascular diseases [23]. miRNAs have also
been reported to play a crucial post-transcriptional role in
CF [24-28]. For example, miR-126 was shown to regulate
the inflammatory signaling pathway and was reported to be
decreased in CF respiratory epithelium as compared to non-
CF bronchial epithelial cells in vivo and in vitro [29]. Like-
wise, TFs are key regulators in the control of gene expres-
sion by translating cis-regulatory codes [30]. Due to their
function and regulatory logic [31], miRNA and TFs co-
regulate the same genes in a complex manner and are there-
fore suitable elements to construct FFLs.
We therefore hypothesized the existence of a set of
FFLs which are composed of both TFs and miRNA to
regulate genes in CF and CFTR. Consequently, we con-
structed CF and CFTR-specific FFLs, and studied the ef-
fects of market drugs by inferring perturbations of
disease-specific FFLs with the aim to determine their po-
tential utility in the treatment of CF. We focused on ap-
proved drugs without boxed warning and are considered
to be safe at affordable prices. As a result, we identified
market drugs as putative candidates for CF treatment.
Strikingly, out of the 48 repurposing drug candidates 26
were confirmed with literature reports and/or existing
clinical trials relevant to the treatment of CF patients
thus providing evidence for the utility of the employed
approach.
Material and methods
CF and CFTR associated gene regulations
Initially, we collected information from diverse public re-
positories including the Genetic Association Database
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Inheritance in Man (OMIM) [36,37], the Function disease
ontology annotation (FunDO) [38,39], and PubMed reports
(see also Table 1). The broad and diverse information was
validated by different experimental platforms. Eventually, a
comprehensive list of differentially expressed genes (DEG)
was compiled using diverse data sets from cystic fibrosis
patients with mild and severe lung disease based on tissue
samples obtained from bronchial brushings or nasal
epithelium as well as rectal epithelia of CF and non-CF
individuals (GEO submission GSE2395, GSE55146, and
GSE15568). Collectively, a total of 1,042 DEGs were
compiled (Additional file 1: Table S1). To discern CFTR-
associated gene regulations from CF-related DEGs the data
reported by Ramachandran et al. [25] were considered and
included 419 unique genes (Additional file 1: Table S1).
MiRNA networks of CF-regulated genes
(miRNA→ gene/TF)
To identify CF-specific miRNAs, data from different sources
were integrated, including a literature search using the key-
words ‘miRNA’ and ‘cystic fibrosis’ in PubMed. Here, we fo-
cused on miRNA expression profiling studies in CF patient
samples and considered particularly the findings of Oglesby
et al. [40] and Bhattacharyya et al. [41] which had informa-
tion on 93 and 22 regulated miRNAs, respectively.
Furthermore, to be able to distinguish between CF and
CFTR miRNAs networks and to identify commonly reg-
ulated ones, data obtained from well-differentiated pri-
mary human airway epithelial cultures were considered
as reported in Ramachandran et al. [25]. There were 112
CFTR associated miRNAs of note (Additional file 2:







Bhattacharyya et al. data 22






Nasal respiratory epithelial (GSE2395) 565
Human bronchial epithelium (GSE55146) 393
Human epithelial cells (GSE15568) 96MiRNA analysis and target prediction was done with
the TargetScan algorithm [42] and included the search
for the presence of conserved 8mer or 7mer sites that
match the seed region of the miRNA. The functional an-
notation of predicted targets is based on experimental
validation [43,44] and in the case of miRNA→ gene/TF
pairs to be considered conserved in homo sapiens a total
context score higher than -0.4 was applied [45]. To con-
firm miRNA targets in CF and CFTR networks and to
distinguish among individual TFs involved, the predicted
target genes were mapped onto a human TFs list in the
ChIPBase [46].
Transcription factor networks of CF regulated genes
(TF→ gene/miRNA)
The TF and gene/miRNA relationship data were extracted
from the ChIPBase [46]. ChIPBase aims to provide high
confident information on the transcriptional regulation of
long non-coding RNA and miRNA genes from ChIP-Seq
data. The data were curated from sources such as the NCBI
GEO database [47], ENCODE [48], the modENCODE data-
bases [49,50], and PubMed literature citations. Thus, the
TFs related to CF and CFTR gene/miRNA networks were
extracted from the human hg19 organism with regulatory
regions (upstream: 5 kb; downstream: 1 kb).
CF protein-protein interaction network
The STRING 9.1 version [51] was applied to study protein-
protein-interaction (PPI) using input data derived from [27]
and CF patient samples (GEO submission GSE2395,
GSE55146, and GSE15568). Initially, a total of 123 CFTR-
associated genes were considered and based on 80 genes





Liu et al. Genome Medicine 2014, 6:94 Page 4 of 17
http://genomemedicine.com/content/6/12/94were observed. Furthermore, for nine disease-specific FFLs
and the 66 genes associated with it, a total of 97 PPIs were
observed. Additionally, for nine out of 15 FFLs the disease-
specific regulation of miRNA was validated by a consensus
approach by employing 10 different algorithms, that is,
DIANA-microT [52], miRanda [53], miRDB [54], miRWalk
[55], RNAhybrid [56], PICTAR4 [57], PICTAR5 [57], PITA
[58], RNA22 [59], and TargetScan [60] (see Figure 1). Gene
targets were considered positive only when confirmed by at
least eight algorithms. Importantly, the STRING analysis
provided high confidence PPI interactions based on the
neighborhood, gene fusion, co-occurrence, co-expression,
experiments, text-mining, and so on. In this study, only in-
teractions with confidence scores higher than 0.4 were
extracted.
Enrichment of significantly regulated miRNA and TF in CF
gene networks
To assess the statistical significance for genes that were
co-regulated by both miRNA and TF, the cumulative
hypergeometric test was employed based on the com-
mon CF and CFTR-specific genes of any pair of miRNA
and TF as described by the following formula [45]:












where NmiR denotes the number of target genes for a
given miRNA, NTF represents the number of target
genes for the corresponding TF, and Total is the number
of common genes between all the CF- and CFTR-related
genes regulated by TFs and repressed by miRNAs. The
Benjamini-Hochberg multiple testing corrections were
used to adjust the P values (function mafdr.m from
MATLAB 7.10.0 (R2010a)), and only those pairs with
justified P values less than 0.05 were considered.
Drug effects on miRNA expression
The effects of drugs on individual miRNAs were com-
piled from SM2miR [61]. In the present study, only
FDA-approved drugs were considered to be potential
repurposing candidates for CF. Moreover, the miRNA-
gene-drug relationship was extracted from Pharmaco-
miR [62] that provides miRNA pharmacogenomics data
manually curated from literatures.
Results
CF- and CFTR-related gene and miRNA expression
changes
An outline of the work flow is given in Figure 1, and a sum-
mary of CF- and CFTR-related gene and miRNA data are
given in Table 1. Initially, a comprehensive list of differen-
tially expressed genes (DEG) was compiled using diversedata sets from CF patients in addition to literature findings
regarding CFTR-associated gene networks. Subsequently,
common regulations of DEGs by TFs and miRNAs were in-
vestigated by means of databases searches in addition to ex-
perimental data retrieved from literature searches.
For this purpose, the publically available GEO data sets
GSE2395, GSE55146, and GSE15568 were analyzed. The
data informed on whole genome gene expression profiling
in cystic fibrosis patients with mild and severe lung disease
using either tissue samples obtained from bronchial brush-
ings or nasal epithelium as well as rectal epithelia of CF
and non-CF individuals. In all 1,042 DEGs were obtained,
however there was little to no overlap among DEGs when
individual studies were compared (see Figure 2A).
Furthermore, to discriminate CF-specific and CFTR-
related miRNA networks profiling data obtained from CF
patient airway epithelium and CF related cell lines as well
as primary human airway epithelium were considered
using the findings reported by Oglesby et al. [40] and
Bhattacharyya et al. [41]. As denoted for the whole gen-
ome gene expression profiling studies major discrepancies
among the reported miRNA profiling studies were ob-
served with little overlap in identified miRNAs using
either bronchial brushings from CF patients or CF bron-
chial epithelial cell lines (see Figure 2B). In regards to
the CFTR associated miRNA regulations the data reported
by Ramachandran et al. [25] were used and yielded 112
differential expressed miRNAs. As depicted in Figure 2C,
31 down- and 12 upregulated miRNAs were in common
when the findings of Oglesby et al. and CFTR-associated
miRNAs were compared as determined in human airway
epithelium. Likewise, two down- and 10 upregulated miR-
NAs were commonly regulated when the data reported by
Bhattacharyya et al. and findings from CFTR-associated
miRNAs were compared (Figure 2D). Taken collectively, a
total of 93, 22, and 112 uniquely regulated miRNAs were
extracted from experimental data and among the three
studies seven miRNAs were in common that permitted an
in-depth assessment of the miRNA-CF disease relationship.
Apart from CF-specific gene and miRNA expression
changes several of the identified genes are also co-expressed
or are involved in the same pathways or biological process
as determined for the CFTR-associated gene network using
human airway epithelium. This is consistent with our under-
standing of the pathogenesis of CF with most of the
common regulated genes influencing folding, sorting, and
degradation of proteins and included the ubiquitin mediated
proteolysis, protein processing in the endoplasmic reticulum
and the proteasome. It has been established that the
ubiquitin-proteasome pathway controls the degradation of
CFTR and therefore plays a central role in CF .
To be able to construct FFLs, different types of regulatory
relationships were considered, that is, genes regulated by ei-
ther miRNA (miRNA→ gene) or TF (TF→ gene), as well
Figure 1 An outline of the work flow.
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Figure 2 VENN diagram of CFTR- and CF-related gene and miRNA expression changes. (A) Common genes among three independent CF
patient-related whole genome gene expression data sets; (B) common miRNAs identified in bronchial brushings from CF patients or CF bronchial
epithelial cell lines; (C) commonality among 112 CFTR- and CF-related miRNAs derived from the study of [40]; (D) commonality among 112 CFTR-
and CF-related miRNAs derived from the study [41].
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vice versa (miRNA→TF and TF→miRNA) in addition to
the gene-gene interaction as depicted in the work flow dia-
gram (Figure 1 and Table 2). The findings entrained on the
CFTR gene and miRNA networks were validated using data
derived from CF patients as detailed in Table 2.
miRNA gene target relationship
Initially, the miRNA targets were predicted using TargetS-
can (see the Method Section for further details and
Table 2). There were a total of 1,615 miRNA→ gene pairs,
which involved 99 CFTR specific miRNAs (out of 112
miRNAs identified) and 226 CFTR-regulated genes (out of
419 genes identified from Reference [25]). Among them,
the miRNAs, hsa-miR-200b, hsa-miR-200c, and hsa-miR-
429 regulated the largest number of genes. The average
number of targeted genes per miRNA is 16.It is well known that the miRNAs from the same family
share similar regulatory functions and mechanisms [63].
We therefore constructed a miRNA-based network using
the CF gene information and investigated whether the re-
lationship between the miRNAs from the same family was
preserved as a means to verify the chosen approach.
Figure 2 depicts the miRNAs network module where each
node is a CF miRNA while an edge denotes the Tanimoto
similarity between each of the two miRNAs. It can there-
fore be demonstrated that the miRNAs from the same
family (for example, hsa-let-7a/b/c/e/g) were preserved
with higher Tanimoto similarity. Likewise, in the con-
structed miRNA-gene network NEDD4L was regulated by
33 miRNAs. This gene codes for an E3 ubiquitin protein
ligase and knockdown of NEDD4L in lung epithelia causes
airway mucus obstruction, goblet cell hyperplasia, inflam-
mation, fibrosis, and even death after 3 weeks of exposure
Table 2 Summary of five different kinds of regulatory relationship and constructed FFLs
Relationship Counts miRNAs (n) mRNAs (n) TFs (n)
Five regulatory relationships miRNA→mRNA 1,615 99 226 -
miRNA→ TF 422 89 - 52
TF→miRNA 3,295 102 - 114
TF→mRNA 16,860 - 387 105
gene-gene 237 123
Three categories of FFLs miRNA FFLs 41 27 128 26
TF FFLs 393 74 218 64
Composite FFLs 15 12 104 11
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support the relevance of the constructed miRNA-gene
network.
Using ChIPBase, a total of 422 miRNA→TF pairs were
identified and consisted of 89 CFTR-specific miRNAs and
52 human TFs. Among the 422 miRNA→TF pairs, hsa-
miR-27a was involved in the regulation of 14 TFs. Mean-
while, the genes BCL11A, SMAD2/3, and SMAD4 were
regulated by the largest number (n =30) of miRNAs. Note,
reduced SMAD3 protein expression and altered TGFβ1-
mediated signaling in CF epithelial cells were reported [65].
TF-miRNA/gene regulatory networks
TF→miRNA circuitries were constructed using infor-
mation retrieved from ChIPBase [46]. A total of 3,295
TF→miRNA combinations were computed and this in-
volved 114 and 102 unique TFs and miRNAs, respect-
ively (see Additional file 3: Table S3). For instance, hsa-
miR-106b, hsa-miR-25, and hsa-miR-93 were regulated
by 72 TFs. Similarly, a total of 16,860 TF-gene pairs
were computed and involved 105 TFs and 387 gene
targets (see Additional file 3: Table S3). Of the 99 TFs,
c-Myc targeted the largest number of CFTR-related
genes. It was earlier demonstrated that proteolysis of c-
Myc in vivo is mediated by the ubiquitin-proteasome
pathway [66]. Among the 387 CFTR-related genes, the
gene regulated by the largest number of TFs was
UBE2D3 (ubiquitin-conjugating enzyme E2 D3). We fur-
ther searched for common genes among CFTR and
1,042 DEGs and found 38 genes to be mutual.
CFTR-specific feed-forward loops (FFLs)
It had been demonstrated that composite FFLs (that is,
the combined miRNA and TF participating in the regu-
lation of target genes) are more effective in unveiling
disease mechanisms than single one as denoted by TF→
miRNA or miRNA→TF considerations [45]. As shown
in the third step of Figure 1 and as summarized in
Table 2, FFLs were evaluated for their significance using
a hypergeometric test with multiple testing corrections.
Such analysis revealed 449 unique CFTR-entrained FFLsincluding 41 miRNA-FFLs, 393 TF-FFLs, and 15
composite-FFLs, as shown in Additional file 3: Table S3.
The results indicated that the constructed composite-FFLs
were of largest relevance followed by miRNA-FFLs and TF-
FFLs. Therefore, and based on statistical significance the 15
composite FFLs were employed to search for repurposing
candidates for the treatment of CF (Additional file 4:
Figure S1). These FFLs contained 12 miRNAs, 11 TFs, and
104 CFTR-related genes, respectively.
We further considered the results of the Kyoto
Encyclopedia of Genes and Genomes (KEGG) pathway
analysis for the commonly targeted genes of the 15
composite-FFLs. Some composites FFLs, such as hsa-
miR-192↔CTCF and hsa-miR-191↔TCF7L2, just have
one gene in common; thus no enriched pathways were
obtained. As depicted in Additional file 5: Figure S2, 24
different pathways belonging to 13 different functional
categories were considered. Among them, two pathways,
ubiquitin-mediated proteolysis and protein processing in
the endoplasmic reticulum, dominated the composite
FFLs, whose major function is folding, sorting, and
degradation and these are key mechanism in CF [67].
Other FFLs are involved in insulin and TGF-beta signal-
ing pathways and endocytosis. For instance, CF-related
diabetes (CFRD) is a common complication of CF and
insulin resistance may also affect lung function [68].
Likewise, transforming growth factor-beta (TGF-beta)
plays a central role in fibrosis, contributing to the influx
and activation of inflammatory cells, the epithelial to
mesenchymal transdifferentiation (EMT) of cells, and
the activation of fibroblasts and modulation of extracel-
lular matrix production [69]. Downregulation of CFTR
by TGF-beta limits epithelial chloride secretion, which
causes mucus block [70]. It was also reported that CF is
associated with a defect in apical receptor-mediated
endocytosis [71].
Validation of FFLs in CF patient samples
To determine disease relevance of the FFLs and to study
protein-protein-interactions (PPI) among members of
the composite FFLs the following data were considered:
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profiling studies using samples obtained from bronchial
brushings or nasal epithelium as well as rectal epithelia
of CF patients with mild and severe disease and non-CF
individuals.
Initially, a total of 123 CFTR genes were retrieved
from the study of Ramachandran et al. and for 80 genes
a total of 135 PPIs were observed in STRING network
analysis. This demonstrates that the network partners
actually interact with each other. Moreover, for seven
and nine disease-regulated miRNAs and TFs, respect-
ively, a total of 97 PPIs among 66 regulated genes were
observed further evidencing interactions among the pre-
dicted targets (see Figure 3).
Subsequently, we considered disease regulated miRNA
and its directionality based on CF patient samples and
therefore analyzed the data of Oglesby et al. [40] and
Bhattacharyya et al. [41] with respect to the composite
FFLs. This revealed a total of seven miRNAs (hsa-miR-
26b, hsa-miR-29c, hsa-miR-135b, hsa-miR-155, hsa-miR-
192, hsa-miR-200c, and hsa-miR-340) and nine FFLs to
be CF associated. Note, in the case of miR-155 threeFigure 3 Protein-protein interaction networks of CFTR-related genes.
et al. of which 123 could be mapped to the STRING database version 9.1. O
score >0.4 was requested. Among them we considered those genes linked
and a total of 135 PPIs to be in common. Subsequently, for nine disease-spedifferent TFs are involved, that is, SP1, NFKB1, and
EBF1, therefore giving rise to three distinct disease-
relevant FFLs. We considered miRNAs whose expression
was either increased or decreased in CF patient samples
(see Figure 4). In order to predict targets of disease asso-
ciated FFLs we employed a consensus approach using 10
different algorithms (see Additional file 6: Figure S3).
The predicted gene targets were considered positive only
when confirmed by at least eight different algorithms.
Apart from disease specific miRNAs that were used to
construct FFLs the regulation of target genes was also
considered in CF patient samples. As described above
we compiled a total of 1,042 DEGs derived from GEO
submissions GSE2395, GSE55146, and GSE15568, and
observed DEGs to be commonly regulated in CF sam-
ples and disease-specific FFLs, once again providing evi-
dence for the clinical relevance (see Figure 5).
Repurposing candidates for the treatment of CF
Drug repositioning is a process of identifying alternative
indications for existing drugs with acceptable safety at
affordable price. To identify drugs with potential use inA total of 419 genes were retrieved from the study of Ramachandran
nly PPI interaction for homo sapiens were considered and a confidence
to the 15 composite FFL that were constructed. This revealed 80 genes






























Figure 4 Composite FFLs of CF-regulated miRNAs. The nodes are marked as green diamonds whereas blue rectangles and gray ellipses
denote transcription factors (TF), miRNAs and genes, respectively. Genes color-coded in red are among the 1,042 CF gene expression data
retrieved from three independent CF gene expression data sets. The edges are t-shapes, circle-shapes, and gray solid lines, which denotes
miRNAs regulating genes/TF and TFs regulating genes/miRNAs, and gene-gene interaction, respectively.
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cules that affect the expression of miRNA which are part
of the composite FFLs. We retrieved data from two data-
bases (that is, SM2miR and Pharmaco-miR) as described
in Figure 1. Notably, the SM2miR compiles a list of
small molecules that interact with miRNAs from the lit-
eratures while Pharmaco-miR provides the drug-miRNA
association based on the PharmGKB data [72]. We then
compared the marketed drug list from DrugBank (ver-
sion 3.0, [73]) with those identified by SM2miR and
Pharmaco-miR as having an ability to influence the ex-
pression of miRNA which are part of the FFLs. This
process identified 48 unique drugs being strongly desig-
nated as repurposing candidates for the treatment of CF
patients.
To assess the validity of the CF repurposing candi-
dates, we conducted a two-step analysis. First, we quer-
ied clinicaltrials.gov (www.clinicaltrials.gov) that archives
clinical studies of human subjects conducted around theworld. Collectively, Table 3 compiles all 48 repurposing
candidates for CF along with their original indications
and literature/clinical trial data. Note that eight out of
48 drugs were already investigated for the treatment of
CF patients. For the remaining drug candidates we add-
itionally queried PubMed using the keyword (‘drug
name’ (and) ‘cystic fibrosis’) followed by reading. Here,
18 out of 43 repurposing candidates have literature cita-
tions to support their potential use in CF. Collectively,
we found 54.2% of the candidates (26 drugs out of 48 re-
purposing candidates) to have at least one published
study or clinical trial related to CF. Additional file 7:
Table S4 lists the information of all 48 repurposing can-
didates related to drug safety and affordability that were
obtained from the FDA-approved drug product labels
and the DrugBank V3.0 database.
We further assessed the therapeutic indications of the
repurposing candidates and found two categories, that
is, Alimentary tract and metabolism (P <0.0016) and
263 gene targets predicted
Consensus approach amongst 10 algorithm to predict 
gene targets of 7 CF disease regulated miRNAs  
138 gene targets with 247 proven PPIs
7 CF regulated genes with 19 PPIs
Genes not expressed in CF patients
Genes expressed in CF patients
Figure 5 Protein-protein interaction networks of CF-related miRNA. A total of 7 CF regulated miRNAs were used to predict gene targets by
employing a total of 10 different algorithms. This defined 263 putative targets which were mapped to the STRING database version 9.1 and
revealed 247 PPI among 138 gene targets. Only PPI interaction for homo sapiens were considered and a confidence score >0.4 was requested.
The predicted 138 gene targets were mapped to 1,042 DEGs identified among three independent CF patient-related whole genome gene
expression data sets. This identified seven genes in common and a total of 19 PPI.
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to be significantly enriched. For the different therapeutic cat-
egories of the 48 drug repurposing candidates see Figure 6.
Note that the two therapeutic categories include some drugs
with boxed warning that need to be considered.
Discussions
This study aimed to define suitable drug repurposing can-
didates for the treatment of CF. For this purpose, FFLs
were entrained on CFTR and CF gene networks. Applying
FFLs to an entire drug landscape is a complex undertaking
and next to safety, affordability was considered. In all 41
miRNA-FFLs, 393 TF-FFLs, and 15 composite FFLs were
computed. Using diverse computational strategies gene
targets were predicted based on disease-regulated miRNA
and involved a consensus approach among different algo-
rithms (see Additional file 6: Figure S3). Validation was
achieved with CF patient sample-specific information and
FFLs were used to enrich the repurposing drug candidate
pipeline by considering small molecules effects on miRNA
expression. Eventually, 48 repurposing candidates were
obtained; their usefulness was considered based on clinicaltrial information, literature findings, safety concerns, and
affordability points of view.
Based on its ability to influence miR-26b [74] and the
transcription factor CREBBP [75], dexamethasone was con-
sidered as a repurposing candidate. Dexamethasone is a
potent steroid and acts as an anti-inflammatory and im-
munosuppressant. Its use in CF patients is consistent with
the current practice of glucocorticoids in the treatment of
lung inflammation [76]. It was reported that low doses of
dexamethasone delivered by autologous erythrocytes slows
the progression of lung disease in CF patients [77]. As
dexamethasone is an approved prescription drug without
boxed warning, it provides additional value for its applica-
tion in CF.
The employed testing strategy also predicted statins as
interesting repurposing candidate and it was reported
that statins retain ceramide levels normal in CF patients
[78,79]. As ceramides and sphingolipids are components
of lipid rafts, they play deceive roles in transmembrane
signaling [80]. We found simvastatin to be implicated in
the hsa-miR-200c↔JUN regulatory FFL. However, some
statins are associated with severe adverse drug reactions,
Table 3 Summary information of 48 repurposing candidates for cystic fibrosis (CF) treatment
Repurposing
candidates
Original indications Notes Confirmation
sources
Evidence found from clinic trials (clinicaltrials.gov)
Simvastatin Hypercholesterolemia; lower cholesterol Simvastatin will increase nitric oxide (NO) produced
(exhaled NO), and may decrease airway inflammation
NCT00255242
Pyruvic acid Dietary shortage or imbalance The inhalation of sodium pyruvate may reduce lung
damage in patients with CF by its ability to reduce
levels of toxic reactive oxygen and nitrogen
compounds associated with the chronic inflammatory
component of the disease
NCT00308243
Pioglitazone Type 2 diabetes Pioglitazone may decrease inflammation in CF lung
disease
NCT00322868
l-Glutamine Dietary shortage or imbalance Patients with CF develop frequent and potentially
life-threatening lung infections. The nutrient
glutamine may help the body fight off infection
NCT01051999
Desipramine Neuropathic pain; attention deficit hyperactivity
disorder; anxiety disorders
Combination of desipramine and VX-770 for CF
treatment
NCT01153542
Nitric oxide Neonates with hypoxic respiratory failure Exhaled nitric oxide (NO), elevated in most
inflammatory lung diseases, is decreased in CF,
suggesting decreased formation, increased metabolism




Choline Dietary shortage or imbalance Nutrition and methyl status of children with CF could
be improved after supplying a choline supplement
NCT01070446
l-Leucine Prevention of the breakdown of muscle proteins A high-leucine essential amino acids mixture
specifically designed to stimulate protein anabolism




Fluoxetine Depression; obsessive-compulsive disorder; antiviral It was suggested that a hydrophobic interaction with
high affinity between uncharged fluoxetine and
volume-activated chloride channels. Ca2+-activated
Cl- currents and CFTR are also blocked by fluoxetine,




Cyclosporine Transplant rejection; rheumatoid arthritis; severe
psoriasis
These results suggest that cyclosporine can be
beneficial as a steroid sparing agent in CF patients
PMID:
11213776
Morphine Severe pain Inhaled morphine to relieve dyspnea in patients with
end-stage lung disease due to CF
PMID:
10973044
Methotrexate Gestational choriocarcinoma; chorioadenoma
destruens; hydatidiform mole; psoriasis; rheumatoid
arthritis
It was suggested an effective systemic anti-
inflammatory effect of methotrexate in treatment for
CF patients with advanced pulmonary disease
PMID:
12735666
Vitamin C Used to treat vitamin C deficiency, scurvy, delayed
wound and bone healing, urine acidification, and in
general as an antioxidant. It has also been
suggested to be an effective antiviral agent
The pool of vitamin C in the respiratory tract represents
a potential nutraceutical and pharmaceutical target for
the complementary treatment of sticky airway
secretions by enhancing epithelial fluid secretion
PMID:
14993613
Dexamethasone Anti-inflammatory; oncologic uses; glucocorticoid
resistance; obstetrics; high altitude illnesses
Low doses of dexamethasone constantly delivered by
autologous erythrocytes slow the progression of lung
disease in CF patients
PMID:
15223012
l-Arginine Treating dietary shortage or imbalance It was suggested that airway nitric oxide formation in








Tamoxifen Breast cancer This inhibition of Ca2+ signaling was prevented and
even potentiated by estrogen antagonists such as
tamoxifen, suggesting that antiestrogens may be
beneficial in the treatment of CF lung disease because
they increase Cl- secretion in the airways
PMID:
19033671
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Table 3 Summary information of 48 repurposing candidates for cystic fibrosis (CF) treatment (Continued)
Rosiglitazone Type 2 diabetes It was suggested rosiglitazone as important modulators
of intestinal Cl- secretory function
PMID:
19443733
Vorinostat Cutaneous T cell lymphoma Vorinostat (SAHA) could restore surface channel activity
in human primary airway epithelia to levels that are
28% of those of wild-type CFTR
PMID:
19966789
Metformin Type 2 diabetes; prediabetes; polycystic ovary
syndrome; gestational diabetes
The metabolic sensor AMP-activated kinase (AMPK)
inhibits both the CFTR Cl(-) channel and epithelial
Na(+) channel (ENaC), and may inhibit secretion of
proinflammatory cytokines in epithelia
PMID:
19617399
Estradiol Urogenital 17Beta-estradiol inhibits IL-8 release by ERbeta in CF
bronchial epithelial cells through upregulation of
secretory leucoprotease inhibitor, inhibition of nuclear
factor (NF)-kappaB, and IL-8 gene expression. These
data implicate a novel anti-inflammatory mechanism




Chloroquine Malaria; strains of P. falciparum; rheumatoid arthritis Vasculitis is a well recognized complication of CF. There
is a case of steroid-resistant cutaneous vasculitis which
was successfully treated with chloroquine in addition




Sirolimus Prophylaxis Autophagy stimulation by sirolimus (rapamycin)
suppresses lung inflammation and infection by
Burkholderia cenocepacia in a model of CF
PMID:
21997369
Nifedipine Vasospastic angina; chronic stable angina;
hypertension; Raynaud’s phenomenon
Nifedipine may be a useful adjuvant to supplemental




Levamisole Dukes’ stage C colon cancer; worm infestations Levamisole could block K+ channels required for Cl
(-)-secretory responses elicited by diverse pathways in
model epithelia and native colon, an effect that





Dietary shortage or imbalance It was reported that extracellular adenosine
triphosphate (ATP) and adenosine were important
luminal autocrine and paracrine signals that regulated
the hydration of the surface of human airway epithelial




Potential candidates for CF treatment




Imatinib Philadelphia chromosome positive chronic myeloid
leukemia (CML); malignant gastrointestinal stromal
tumors (GIST)
Gemcitabine Metastatic breast cancer
Dienestrol Atrophic vaginitis; kraurosis vulvae




Warfarin Retinal vascular occlusion; pulmonary embolism;
cardiomyopathy; atrial fibrillation and flutter;
cerebral embolism; transient cerebral ischemia;
arterial embolism; thrombosis
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Table 3 Summary information of 48 repurposing candidates for cystic fibrosis (CF) treatment (Continued)




Fluorouracil Multiple actinic; solar keratoses
Mercaptopurine Acute lymphatic leukemia
Cetuximab EGFR-expressing metastatic colorectal cancer;
squamous cell carcinoma
Dopamine Hemodynamic imbalances




Dietary shortage or imbalance
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http://genomemedicine.com/content/6/12/94most notable rhabdomyolysis. For this reason cerivastatin
had been withdrawn from the market [81]. In a clinical
trial (NCT00255242) the beneficial effect of simvastatin in
alleviating airway inflammation in CF patients was investi-
gated [82] and statins without boxed warning in the label
are interesting repurposing candidates.Figure 6 The distribution of repurposing candidates for CF at the firs
(ATC). Each bar was divided by safety concerns including boxed warning,
significance of the therapeutic categories associated with CF are A and L bLikewise, phenylimidazothiazoles were reported to ac-
tivate wild-type and mutant CFTR in transfected cells
and thus, have been proposed as drug remedy for CF
[83,84]. The present study inferred levamisole to perturb
the hsa-mir-26b↔CREBBP and hsa-miR-200c↔JUN
FFLs and this drug was used to treat Dukes’ stage Ct level of Anatomical Therapeutic Chemical Classification System
no boxed warning, and nutritional supplementation. The statistical
ased on the Fisher’s exact test with a P value cutoff of 0.01.
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http://genomemedicine.com/content/6/12/94colon cancer and worm infestations. It was demon-
strated that levamisole inhibited intestinal Cl- transport
via basolateral K+ channel blockade [85] and this pro-
vides a molecular rational for further evaluation.
In another clinical trial (NCT01070446), the effects of
choline supplementation in children with CF was inves-
tigated. Note, children with CF are reported to have de-
pleted levels of choline [86] and choline is involved in
two composite FFLs including hsa-miR-200c↔JUN and
has-miR-29c↔TFAP2C as per our investigations.
Furthermore, among the repositioning candidates were
thiazolidinediones (TZD), which were initially used to
treat type-II diabetes. This class of drugs includes both pi-
oglitazone and rosiglitazone. Some evidence exists that
TZD could be used to ameliorate the severity of the CF
phenotype [87]. Pioglitazone and rosiglitazone are known
to activate peroxisome proliferator-activated receptor
gamma (PPARγ) and it has been suggested that a revers-
ible defect in PPARγ signaling in Cftr-deficient cells could
improve the severity of the CF phenotype in mice. Add-
itionally, in clinical trial NCT00322868 pioglitazone was
evaluated for its ability to decrease inflammation in CF
lung patients. While thiazolidinediones are promising, un-
fortunately this class of drug has been reported to exacer-
bate congestive heart failure in some patients and thus are
labelled with a boxed warning. In addition, troglitazone
was withdrawn from the market due to severe liver
toxicity [88].
The performed analysis also identified some anti-cancer
drugs for potential use in CF patients [89,90] and it was hy-
pothesized that induction of homologous recombination in
respiratory epithelium helps to improve the lung function
of patients [90]. In our analysis, vorinostat (SAHA), a
histone-deacetylase inhibitor and anti-cancer drug used to
treat cutaneous T-cell lymphoma, appeared to be a reason-
able repurposing candidate. This drug was reported to re-
store surface channel activity in human primary airway
epithelia to a level that was 28% of wild-type CFTR and
does not have a boxed warning, but is fairly expensive.
The developed drug repurposing strategy is a modular
system and each of the components can be modified or even
replaced by other algorithms. Besides TargetScan there are
alternatives approaches such as RNAhybrid [56], DIANA-
microT [52], RNA22 [59], miRanda [53], PicTar [57], and
miRWalk [55] to predict gene targets. Indeed, it has been
suggested that combining diverse algorithms could provide
more confidence in the inferred drug miRNA-gene relation-
ships [20,91]. To this effect we employed a consensus ap-
proach for predicting gene targets of disease-regulated
miRNAs by using 10 different algorithms. Lastly, the direc-
tions of the disease-regulated miRNAs were considered and
the consensus approach revealed that 48% of the predicted
targets by TargetScan could be confirmed by at least another
algorithm. Moreover, for the TF binding site predictions, weutilized experimental data retrieved from ChIP-Seq experi-
ments. Other technologies such as CHIP on chip array or in
silico approaches based on position weight matrices can also
be employed to identify putative transcription factor binding
sites [92].
The present study focused on repurposing candidates
from the miRNA-small molecule perspective while the
relationship between TFs and small molecules, that is,
drugs affecting transcription factor expression and activ-
ity was not considered in detail. So far only a few drugs
target TF and would therefore limit the choice of drug
repurposing candidates; nonetheless drugs targeting TFs
will increase with time [93]. A recent study demon-
strated heat shock transcription factor 1 (HSF1) as a po-
tential new therapeutic target in multiple myeloma [94]
and other studies revealed that nuclear transcription
factor-kappa B (NFκB) could be a potential target for
drug development in different disease entities [95-97].
We also found NFκB to be involved in several
composite-FFLs including has-miR-155↔NFκB and has-
miR-340↔NFκB. Note that ibuprofen, a non-steroidal
anti-inflammatory drug (NSAID), is one of the anti-
inflammatory therapies used in the treatment of CF
[98,99]. It has been demonstrated that high dose ibupro-
fen causes modest suppression of NFκB transcriptional
activity in CF respiratory epithelial cells. Furthermore,
miR-155 promotes inflammation in CF by driving hyper-
expression of interleukin-8 [41]. In future studies, the
transcription factor drug relationship will be explored in
greater detail.
The goal of drug repurposing is to bring new therapies
to the market at a lower risk, reduced cost, and less devel-
opment time when compared to conventional drug devel-
opment programs [100]. However, the safety assessment
in a new disease indication is still an important concern in
the regulatory process. While the safety assessment is
based on drug label information, the drug repositioning
approach may involve different formulations and changes
in dosage that need to be considered in different patient
populations. For instance, the use of high dose ibuprofen
in CF is concerning for its adverse drug reactions, most
notably in causing GI hemorrhage, myocardial infarction,
drug-induced liver injury, and even renal failure [7]. Add-
itional approaches for safety assessment of market drugs
are the U.S. FDA Adverse Event Reporting System
(FAERS) [101] and the FDA’s Sentinel initiative [102]. Fi-
nally, 10% of healthcare expenditure in the U.S. has been
attributed to prescribed drugs [103]. Thus, drug afford-
ability will require consideration.
Conclusion
In conclusion, we report a strategy for the rational selec-
tion of drug repurposing candidates based on miRNA-
TF FFLs. The methodology developed is straightforward
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in other rare diseases.
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